Tracazolate has primarily anxiolytic and anticonvulsant effects, with sedative and muscle relaxant effects only appearing at higher doses. It has a unique receptor binding profile involving allosteric modulation of several GABAA receptor subtypes, being selective for GABAA receptors containing α1 and β3 subunits, but exhibiting different effects depending on the third type of subunit making up the receptor complex.
^Patel JB, Malick JB, Salama AI, Goldberg ME. Pharmacology of pyrazolopyridines. Pharmacology, Biochemistry and Behaviour. 1985 Oct;23(4):675-80. PMID 2866547
^Patel JB, Malick JB. Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent. European Journal of Pharmacology. 1982 Mar 12;78(3):323-33. PMID 6121711
^Thompson SA, Wingrove PB, Connelly L, Whiting PJ, Wafford KA. Tracazolate reveals a novel type of allosteric interaction with recombinant gamma-aminobutyric acid(A) receptors. Molecular Pharmacology. 2002 Apr;61(4):861-9. PMID 11901225